151 related articles for article (PubMed ID: 21331936)
1. PET and PET/CT in the management of thyroid cancer.
Basu S; Urhan M; Rosenbaum J; Alavi A
Methods Mol Biol; 2011; 727():205-24. PubMed ID: 21331936
[TBL] [Abstract][Full Text] [Related]
2. Can (18)F-FDG-PET/CT be generally recommended in patients with differentiated thyroid carcinoma and elevated thyroglobulin levels but negative I-131 whole body scan?
Bannas P; Derlin T; Groth M; Apostolova I; Adam G; Mester J; Klutmann S
Ann Nucl Med; 2012 Jan; 26(1):77-85. PubMed ID: 22006540
[TBL] [Abstract][Full Text] [Related]
3. Thyroid incidentalomas discovered on positron emission tomography CT scanning - Malignancy rate and significance of standardised uptake values.
Brindle R; Mullan D; Yap BK; Gandhi A
Eur J Surg Oncol; 2014 Nov; 40(11):1528-32. PubMed ID: 24915858
[TBL] [Abstract][Full Text] [Related]
4. Fluorodeoxyglucose positron emission tomography (FDG-PET) and PET/computed tomography imaging characteristics of thyroid lymphoma and their potential clinical utility.
Basu S; Li G; Bural G; Alavi A
Acta Radiol; 2009 Mar; 50(2):201-4. PubMed ID: 19089692
[TBL] [Abstract][Full Text] [Related]
5. The role of 18F-Fluorodeoxyglucose Positron Emission Tomography in patients with suspected recurrence or metastatic differentiated thyroid carcinoma with elevated serum thyroglobulin and negative I-131 whole body scan.
Trybek T; Kowalska A; Lesiak J; Młynarczyk J
Nucl Med Rev Cent East Eur; 2014; 17(2):87-93. PubMed ID: 25088108
[TBL] [Abstract][Full Text] [Related]
6. Effect of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography-guided management of suspected recurrent papillary thyroid carcinoma: long-term follow-up with tumour marker responses.
Dennis K; Hay JH; Wilson DC
Clin Oncol (R Coll Radiol); 2012 Dec; 24(10):e168-72. PubMed ID: 22944464
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic accuracy of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in differentiated thyroid cancer patients with elevated thyroglobulin and negative (131)I whole body scan: evaluation by thyroglobulin level.
Na SJ; Yoo IeR; O JH; Lin C; Lin Q; Kim SH; Chung SK
Ann Nucl Med; 2012 Jan; 26(1):26-34. PubMed ID: 21971605
[TBL] [Abstract][Full Text] [Related]
8. Impact of ¹⁸F-FDG PET/CT for detecting recurrence of medullary thyroid carcinoma.
Ozkan E; Soydal C; Kucuk ON; Ibis E; Erbay G
Nucl Med Commun; 2011 Dec; 32(12):1162-8. PubMed ID: 21946617
[TBL] [Abstract][Full Text] [Related]
9. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer.
Finkelstein SE; Grigsby PW; Siegel BA; Dehdashti F; Moley JF; Hall BL
Ann Surg Oncol; 2008 Jan; 15(1):286-92. PubMed ID: 17882493
[TBL] [Abstract][Full Text] [Related]
10. Role of [(18)F]-fluorodeoxy-D-glucose positron emission tomography and computed tomography in the early detection of persistent/recurrent thyroid carcinoma in intermediate-to-high risk patients following initial radioactive iodine ablation therapy.
Kim MH; O JH; Ko SH; Bae JS; Lim DJ; Kim SH; Baek KH; Lee JM; Kang MI; Cha BY; Lee KW
Thyroid; 2012 Feb; 22(2):157-64. PubMed ID: 22224820
[TBL] [Abstract][Full Text] [Related]
11. Could [18]F-fluorodeoxyglucose PET/CT change the therapeutic management of stage IV thyroid cancer with positive (131)I whole body scan?
Piccardo A; Foppiani L; Morbelli S; Bianchi P; Barbera F; Biscaldi E; Altrinetti V; Villavecchia G; Cabria M
Q J Nucl Med Mol Imaging; 2011 Feb; 55(1):57-65. PubMed ID: 21285923
[TBL] [Abstract][Full Text] [Related]
12. Impact of FDG-PET computed tomography for surgery of recurrent or persistent differentiated thyroid carcinoma.
Weber T; Ohlhauser D; Hillenbrand A; Henne-Bruns D; Reske SN; Luster M
Horm Metab Res; 2012 Nov; 44(12):904-8. PubMed ID: 22791600
[TBL] [Abstract][Full Text] [Related]
13. 18-fluorodeoxyglucose positron emission tomography in the early diagnostic workup of differentiated thyroid cancer patients with a negative post-therapeutic iodine scan and detectable thyroglobulin.
van Dijk D; Plukker JT; Phan HT; Muller Kobold AC; van der Horst-Schrivers AN; Jansen L; Sluiter WJ; Brouwers AH; Links TP
Thyroid; 2013 Aug; 23(8):1003-9. PubMed ID: 23517405
[TBL] [Abstract][Full Text] [Related]
14. 18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer.
Shammas A; Degirmenci B; Mountz JM; McCook BM; Branstetter B; Bencherif B; Joyce JM; Carty SE; Kuffner HA; Avril N
J Nucl Med; 2007 Feb; 48(2):221-6. PubMed ID: 17268018
[TBL] [Abstract][Full Text] [Related]
15. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
Vera P; Kuhn-Lansoy C; Edet-Sanson A; Hapdey S; Modzelewski R; Hitzel A; d'Anjou J; Basuyau JP
Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
[TBL] [Abstract][Full Text] [Related]
16. Initial experience in use of fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography in thyroid carcinoma patients with elevated serum thyroglobulin but negative iodine-131 whole body scans.
Ong SC; Ng DC; Sundram FX
Singapore Med J; 2005 Jun; 46(6):297-301. PubMed ID: 15902358
[TBL] [Abstract][Full Text] [Related]
17. Postradioiodine treatment whole-body scan in the era of 18-fluorodeoxyglucose positron emission tomography for differentiated thyroid carcinoma with elevated serum thyroglobulin levels.
Leboulleux S; El Bez I; Borget I; Elleuch M; Déandreis D; Al Ghuzlan A; Chougnet C; Bidault F; Mirghani H; Lumbroso J; Hartl D; Baudin E; Schlumberger M
Thyroid; 2012 Aug; 22(8):832-8. PubMed ID: 22853728
[TBL] [Abstract][Full Text] [Related]
18. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels.
Wang W; Macapinlac H; Larson SM; Yeh SD; Akhurst T; Finn RD; Rosai J; Robbins RJ
J Clin Endocrinol Metab; 1999 Jul; 84(7):2291-302. PubMed ID: 10404792
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of FDG PET/CT on the follow-up of patients of differentiated thyroid carcinoma with negative 131I whole-body scan and elevated thyroglobulin levels: correlation with clinical and histopathologic characteristics and long-term follow-up data.
Vural GU; Akkas BE; Ercakmak N; Basu S; Alavi A
Clin Nucl Med; 2012 Oct; 37(10):953-9. PubMed ID: 22899202
[TBL] [Abstract][Full Text] [Related]
20. The prevalence and clinical significance of (18) F-2-fluoro-2-deoxy-D-glucose (FDG) uptake in the thyroid gland on PET or PET-CT in patients with lymphoma.
Lin M; Wong C; Lin P; Shon IH; Cuganesan R; Som S
Hematol Oncol; 2011 Jun; 29(2):67-74. PubMed ID: 20635328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
